Aslan A - Search Results

1

Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.

Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM. Noret M, et al. Among authors: aslan a. AIDS. 2018 Sep 24;32(15):2161-2169. doi: 10.1097/QAD.0000000000001939. AIDS. 2018. PMID: 30212403

2

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group. De Castro N, et al. Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674. Clin Infect Dis. 2009. PMID: 19757993 Clinical Trial.

3

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Krastinova E, et al. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. PLoS One. 2013. PMID: 23936509 Free PMC article.

4

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufi D, Obadia M, Bernard L, Goujard C, Meyer L; ANRS PRIMO cohort. Krastinova E, et al. BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1. BMC Infect Dis. 2015. PMID: 25888386 Free PMC article.

5

Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group. Chéret A, et al. J Antimicrob Chemother. 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084. Epub 2015 Apr 21. J Antimicrob Chemother. 2015. PMID: 25900157 Clinical Trial.

6

Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.

Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gérard L, May T, Simon A, Vigouroux C, Goujard C; ANRS-COPANA Cohort Study Group. Ghislain M, et al. PLoS One. 2015 Dec 4;10(12):e0144317. doi: 10.1371/journal.pone.0144317. eCollection 2015. PLoS One. 2015. PMID: 26636578 Free PMC article. Clinical Trial.

7

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group. Molina JM, et al. Among authors: aslan a. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8. Lancet Infect Dis. 2018. PMID: 29229440 Clinical Trial.

8

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.

Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group. Pressiat C, et al. J Antimicrob Chemother. 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498. J Antimicrob Chemother. 2018. PMID: 29365125 Clinical Trial.

9

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial.

Hall N, Allavena C, Katlama C, Jobert A, Molina JM, Cua E, Bani-Sadr F, Hocqueloux L, Duvivier C, Merrien D, Hikombo H, André-Garnier E, Gaultier A, Raffi F; QDISS Study Group. Hall N, et al. AIDS Res Ther. 2022 Jan 15;19(1):4. doi: 10.1186/s12981-022-00428-5. AIDS Res Ther. 2022. PMID: 35033092 Free PMC article.

10

A highly virulent variant of HIV-1 circulating in the Netherlands.

Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

830 results

Search Page